Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hope your right bro cause I'm in this so deep I'm done for if it doesn't.
I'm dead!
MM's gonna try and squash any attempt at a reversal here.
gold-leade-r, Add Ocala,Fl CC to list. I just went and asked the manager if he knew of the GZFX deal. He was aware of it but didn't know much about it. I'd update but I'm on my laptop and the battery is about to go.
AMEP moving.
AMEP inching back up.
AMEP
AMEP breakout?
PLNI looks ready to pop!
MUCL news! US Patent Office grants MUCL new Liver Stem Cell Patent.
MUCL news! US Patent Office grants MUCL new liver Stem Cell Patent.
MultiCell Technologies Files Form 10-K; Annual Report Contains No 'Going Concern' Opinion For First Time in Company's History Reflecting Financial Strength and Business Prospects
Business Wire - February 28, 2005 11:10
WARWICK, R.I., Feb 28, 2005 (BUSINESS WIRE) -- MultiCell Technologies, Inc. (MultiCell): (OTCBB:MUCL) announced today that it has filed its 10-K Annual Report with the Securities and Exchange Commission. The report, for the first time in the Company's history, does not contain a "going concern" opinion. Statement on Auditing Standards (SAS) 59 requires auditors, in conducting their annual audits, to consider an entity's ability to continue as a going concern. The auditor will normally reach substantial doubt that an entity can continue as a going concern if the entity is unable to meet its obligations as they become due without substantial disposition of assets outside the ordinary course of business, restructuring of debt or externally forced revisions of its operations or similar actions.
"We are pleased that our auditors have given the Company a clean opinion for the first time in its history," said Anthony Cataldo, MultiCell's Chairman. "This should enhance our ability to enter into strategic relationships and licensing deals and obtain a listing on a national exchange, as investors and potential partners will recognize the improved financial condition and business prospects for the Company. We are excited about the potential for our stem and liver cell technologies."
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE: MultiCell Technologies, Inc.
MultiCell Technologies, Inc.
Jerry Newmin, 401-738-7560
or
CEOcast, Inc. for MultiCell
Ed Lewis, 212-732-4300 x225
Copyright (C) 2005 Business Wire. All rights reserved.
EXTI, Probably a trade between MM'S adjusting inventory.
Good points. I guess I always look at it from the angle of a business owner. It's easier and cheaper to keep the customers you have than to try and find new ones.
Good morning all. We need to figure out how to get more of the RB members to jump ship. How about one of those telcom types of promotions. We'll switch you over for free! LOL
.48 x .485 Vol 701,959
MultiCell's Xenogenics Subsidiary Granted Artificial Liver Device Patent; Sybiol Device Offers Potential To Treat Millions of Patients with Liver Trauma or Insufficiency
WARWICK, R.I., Feb 24, 2005 (BUSINESS WIRE) -- MultiCell Technologies, Inc.
(MultiCell): (OTCBB: MUCL) announced today that its majority owned subsidiary,
Xenogenics Corporation ("Xenogenics"), has been granted U.S. patent 6,858,146 on
its Sybiol(R) synthetic bio-liver device. The '146 patent includes over 40
claims to the device and methods for its use in the purification of a patient's
bodily fluids.
"This long-awaited patent offers the hope of helping many millions of people
with liver trauma or insufficiency around the world," said Jerry Newmin,
MultiCell's CEO. "The company intends to file additional patents covering
further improvements to the Sybiol device and its application."
Xenogenic's synthetic bio-liver device was re-designed to utilize the company's
immortalized human liver cells lines. The Sybiol bio-liver is an extra-corporeal
device designed to support patients who are waiting for liver transplants, who
are suffering from episodic liver disease caused by hepatitis, alcoholism,
cancer, or from burn or toxic shock syndrome or other liver trauma. The device
is designed to increase not only the life spans, but also the quality of life in
afflicted patients.
A sampling of recent liver disease facts clearly shows the need for such a
device:
-- One in every ten Americans are or have been afflicted with
liver and biliary diseases.
-- About 4 million Americans are infected with Hepatitis C virus
alone.
-- Over 87,000 are on liver transplant waiting lists nationwide.
-- Acute liver failure patients die within three days.
MultiCell's cellular expertise enables production of immortalized hepatocytes
and biologics for use in diagnostic and therapeutic applications, as well as
production of liver-derived therapeutic proteins. The Company's majority-owned
Xenogenics subsidiary owns all rights to the patented Sybiol(R) synthetic
bio-liver device, which is intended to operate optimally with MultiCell's
immortalized hepatocytes. Hundreds of millions of people suffer from liver
disease worldwide; treatment options, especially donor organs, are still
limited.
The company's intellectual property portfolio also includes a patent on
liver-derived adult stem cells, the methodology of which avoids the ethical and
contamination issues plaguing embryonic stem cells.
MultiCell's current revenues are derived from providing non-tumorigenic
functional hepatic (liver) cells and cell lines to pharmaceutical companies for
induction studies and toxicity screening for drug discovery. For pricing and
delivery information, contact MultiCell's marketing and manufacturing licensee,
XenoTech, LLC of Lenexa, KS, telephone (913) GET-P450. MultiCell is at 55 Access
Road, Suite 700, Warwick, Rhode Island. For more information about MultiCell and
its Xenogenics subsidiary, call (401) 738-7560 or see www.multicelltech.com.
The matters set forth in this press release are forward-looking statements
within the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are subject to
risks and uncertainties that may cause actual results to differ materially.
These risks are detailed from time to time in the Company's periodic reports
filed with the Securities and Exchange Commission including the Company's Annual
Report, Quarterly Reports and other periodic filings. These forward-looking
statements speak only as of the date hereof. The Company disclaims any intent or
obligation to update these forward-looking statements.
SOURCE: MultiCell Technologies, Inc.
CONTACT: MultiCell Technologies, Inc.
Jerry Newmin, 401-738-7560
or
CEOcast, Inc. for MultiCell
Ed Lewis, 212-732-4300 x225
Patent PR is out!
BKST holding us down again!
Hah! now they drop it to .44
.445 has been hit pretty hard. Got to fall shortly.
MUCL looking good!
wtb and delphi, Nice job getting this thing going!
delphi, Maybe you can help sway some of the RB MUCL members to move over here.I've tried in the past without much success. ihub is so much better.
Looking Good!
Yeah, I don't trade my MUCL been holding for a long time. I did however learn a few lessons the hard way and pretty much wiped out my trading account. When I started trading with my business account my CPA got a little upset so I had to cool it for a while. Good thing I don't depend on trading for a living. LOL
Yeah, I like IHUB much better. I haven't been trading much in the past few months so I haven't been around to often.
Yeah, well that's what you get for having 5 or 6 different alias's LOL
trade, good to see ya!
wantobe, glad to see the effort. Hope you can get some traffic over here. I'd sure rather hang out here instead of RB. By the way, It's nice to have a little humor mixed in with all the technical stuff. Some people just don't get it.
wantoberich, Noticed your recent posts on the RB MUCL board. Figured I'd come over and check out your site. Nice scenery! Been in MUCL for a long time. Huge potential IMO things seem to be falling into place. GLTY
Lance, I mentioned MUCL back in October and noticed you posted about it a few days back. Here is some very thorough DD on this company compiled by an RB MUCL board member. I've been in MUCL for a long time. Not a great stock to trade but IMO huge potential as an investment.
MUCL compendium
http://finance.yahoo.com/q?s=MUCL.OB&d=t
http://exten.com/
quarterly reports - no surprises - the $2M financing not included in 10QSB
8K out on edgar on the $2 million - nothing new - same as PR
http://biz.yahoo.com/bw/040713/135856_1.html
http://www.sec.gov/Archives/edgar/data/811779/000108638004000034/ext8k071304exh991.htm
10QSB quarterly report
http://www.sec.gov/Archives/edgar/data/811779/000108638004000033/extq0504.htm
http://biz.yahoo.com/e/040715/mucl.ob10qsb.html
'The additional royalties we will now begin to receive from XenoTech may be sufficient to cover our cash requirements for ongoing operations.'
There is a huge long term potential gain for holders of MUCL(EXTI) stock at this level. MUCL(EXTI) has a current monopoly on a proprietary patent protected product (adult immortalized self reproducing human liver cells in a proprietary medium - cloned human hepatocytes) that will probably become part of early stage drug research toxicity testing by most all drug development companies because of it's biochemical accuracy of function close to liver reactions in human subjects. This will enable drug research proceedures to avoid costly failures in later drug development stages by screening out clinically proven unviable candidates early in the cash burning process.
MultiCell (MUCL) is poised to grow with the exploding human cell based in vitro testing industry. With the cost of development for the average drug now estimated at over 800 million dollars, pharmaceutical companies desperately need to improve their efficiency when it comes to weeding out new molecular entities that could pose problems in later stage development.
To this end most are investing in more early stage high throughput in vitro testing with human cells (where possible).
Since the majority of drugs now on the market are metabolized in the liver - over half of them by one hepatic enzyme alone - hepatocytes are among the most prized cells for early toxicity screening, drug development, and drug/drug interaction studies.
MultiCell has developed a unique line of liver cells that reproduce endlessly in culture. This cell line, designated as Fa2N-4, could replace primary human liver cells (from cadavers) for use in several types of high throughput early tox screening, enzyme induction, and drug/drug interaction studies.
Primary liver cells are difficult to obtain, not available on any predicable schedule, expensive and labor intensive to prepare, and of inconsistent quality. Also, primaries lose their functionality rapidly when thawed following cryopreservation. MultiCell's immortalized hepatocytes do not.
MultiCell's immortalized liver cells have demonstrated the ability to replace the need for continuous procurement and quality testing of primary cells from donated human livers. Expanded from MultiCell cell banks, these cell lines have significant cost and quality control advantages over primary cell sources. MultiCell's proprietary human immortalized hepatic cell lines radically differ from other immortalized cell lines in that they regenerate while retaining liver function. A prolific cell without function is of no value. These cell lines provide a consistent and functional resource for drug discovery and toxicology research, and can also be applied to liver tissue regeneration.
Previous attempts to create immortalized liver cell lines employed tumorigenic cells which were incapable of generating the necessary P450 enzymes for toxicity induction studies. MultiCell's lines are immortalized using the large SV40 T-antigen in a process that ultimately results in the expression of hTERT, allowing the cells to reproduce indefinitely, yet maintain the enzyme expression profiles of a fully differentiated liver cell.
From a recent study done by Hoffman La Roche, which expanded on similar findings made by Pfizer:
“Conclusion: Fa2N-4 cells performed much like fresh human hepatocytes. Using a panel of inducers, both mRNAs and P450 enzymatic activities were induced. These immortalized cells have potential for use as an alternative to primary human liver tissue for In Vitro Induction Studies.”
•MultiCell has signed a seven-year, eighteen million dollar exclusive distribution deal with XenoTech LLC, a leading cell product provider, and one of the United States' most successful CRO's.
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=29721
This is an in depth report on Multicell's Immortalized Human Hepatocytes:
A New Advance in Convenience and Performance
by David Steen of Xenotech
http://www.currentseparations.com/issues/20-4/20-4h.pdf
The cells are refrred to as Fa2N-4 cells ("Fa" stands for "Dr. Ronald Faris" - MCT's (Multicell's) President & chief scientific officer. CSO ).
MultiCell immortalized primary human hepatocyte cells (via SV40) and produced approximately 100 clonal cell lines.
Out of ~ 100 clones, clone Fa2N-4 is the best clone for induction.
Dr. Parkinson of Xenotech, who markets MUCL's cells "... anticipates that Xenotech may not be able to manufacture enough [of Multicell's immortalized liver Fa2N-4 cells] to keep up with demand and is considering outsourcing additional capacity with a large supplier in Kansas City."
Steen of Xenotech has admitted Roche is using Multicell's cells. XenoTech, a non-public company, is an affiliate of Roche. Steen admitted MUCL's cells are their top-product...
http://www.currentseparations.com/issues/20-4/20-4h.pdf
Fa2N-4 is MCT's non-tumorigenic immortalized
self-replicating human hepatocyte. (clonal hepatocyte)
When assessing any purported competition both
the tumorigenics and metabolism must be considered.
So far, it appears MUCL's product is the "gold standard".
Fa2N-4 cells are superior as explained pretty much sums it up in a nutshell
In contrast to fresh human hepatocytes, Fa2N-4 cells are readily available.
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=31211
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=31221
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=31290
http://otcbb.com/dynamic/tradingdata/daily/graduations.htm
http://home.comcast.net/~dcmack2/CONCLUSIONX.jpg
Conclusion: Fa2N-4 cells performed much like fresh human hepatocytes. Using a panel of inducers, both mRNAs and P450 enzymatic activities were induced. These immortalized cells have potential for use as an alternative to primary human liver tissue for In Vitro Induction Studies
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=8459
IN VITRO INDUCTION OF CYTOCHROME P450S AND DRUG TRANSPORTERS USING THE FA2N-4 IMMORTALIZED HUMAN HEPATOCYTE LINE
Karl Bruce Frank, Hoffmann-La Roche Inc., Nutley, NJ, USA http://issx.org/PDFfiles/provfinal.pdf
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=19764
[...why the drug industry desperately needs Exten's cells -written in 2000 - author is not aware of Multicell]
He writes that "primary" cells--cells from human donors--are the only viable source of hepatocytes. The only other hepatocytes available at the time were tumorigenic and didn't have full enzymatic function. He also describes some of the problems with primary hepatocytes--that known methods of cryopreservation limit their usefulness, and that they aren't readily available.
“We cannot continue to use the organ retrieval and transportation networks as they cannot scale with the exponentially increasing demand for hepatocytes.” – Universtity of Alberta, 2002
During the last 3 to 5 years Pharmaceutical companies came to the conclusion that induction studies are an almost perfect prediction for inhibition studies
"Drug failures or FDA rejections due to hepatotoxicity and/or drug-drug interactions now cost the pharmaceutical industry around $2 billion each year."
ADME/Tox part of the picture was said to be around 5% of the total money spent to bring a drug all the way.
Human livers are a problem in preservation and access.
This is the only company that can grow human liver cells that retain function and DNA non-variability (no mutation) generation after generation from a single parent cell.
87% of drugs fail in clinical trials mostly because of lack of reliable in vitro models. - Dr. Faris
MultiCell Technologies is the only company in the world able to produce DNA-engineered, non-tumorigenic, immortalized, human hepatocytes 24/7. And they have been proven by Roche, Pfizer and XenoTech to be non-variable
Average cost to discover and develop a new drug: $800 million
Average length of time from discovery to patient: 10 to 15 years
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=26397
USA number of drugs under Dev a total of 5840 drugs
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=33825
average weekly throughput of 80,000 wells or more is classified as High-Throughput Screening so Faris's $500M number in the right ballpark
"450-500 HTS labs worldwide".
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34796
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34798
screening, toxicology, and ADME
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34806
$60K per site is for growing cells
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34738
Dr. Parkinson's and Faris' estimates of a $500M market are based on annual use of about 1M 96 well plates using human hepatocytes?
Average HTS lab runs 80,000 wells/week - guesstimates
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=35056
MultiCell MUCL (previously EXTEN Industries OTCBB: EXTI) owns patent rights to these non-tumorigenic, immortalized human liver cells which means they can reproduce indefinitely in-vitro (i.e., in the test tube) and retain the most important characteristics for testing the effects of any new drug/chemical/additive on human beings. Compounds can be tested against these cells and an initial read can be obtained as to what kind of effect they will have on humans. This is a new thing in the world, and MultiCell is the only company that has human liver cells with these characteristics. MUCL is a biotech that has the potential to change the whole drug testing market..
This company differs significantly, in my opinion, from other biotech bulletin board stocks. MultiCell has a proven, marketed product that fills a real need. No FDA approval is needed before sales can occur; sales exist and are increasing. One of the major expenses showing up on SEC filings is protection of MUCL's intellectual property rights. I think it is telling that this expense was paid for by issuing warrants for stock. Expenses have been cut to the bone; employees receive stock as partial payment in lieu of salary. MultiCell is being run as a business, by business people. The company does not indulge in "fluff" press releases, nor do they spend money on "shareholder relations". They are not out "pumping" their stock. This company is flying under the radar of the entire investment community.
The cell lines are proprietary and CAN NOT be duplicated. They are ONE OF A KIND! The proprietary media is needed to make the cells function properly.
This answers the question of corporate piracy and any licensing agreements. They are and will be the only company with these type cells.
"Our proprietary media, which is our own formulation and has been kept as a trade secret, is exclusively used with our immortalized cells to achieve the functions associated with the cells. The cells do not function at the same level without the media."
David Steen of Xenotech confirmed that the pharma industry moves conservatively and gradually, citing the “gestation period of an elephant” as an applicable metaphor.
The greatest delay however is due to our insistence that the pharmaceutical companies sign our user agreements. These agreements are for the protection of our intellectual property. These are extensive but very necessary documents that find their way to the legal departments of the pharmaceutical companies before they will be signed. As you can imagine, they get held up as the company attorney’s attempt to change the terms. We must be patient as this process goes forward.
the previous CEO - Greg Szabo
"It has taken longer than was first anticipated for sales to ramp up. Parkinson believes this was due to an overly burdensome contract. To alleviate this challenge, the contract has been reduced from 12 pages to 4.
The contracts and the initial price structure needed to be modified to satisfy the clients.
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34759
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=26977
Interview with former Exten CEO GREGORY F. SZABO http://www.twst.com/notes/articles/pam604.html
The following is a list of companies who have signed or are preparing to sign licenses to evaluate MultiCell's unique line of readily available, fully functional, immortalized hepatocytes:
Astra Zeneca, Aventis, Amgen, Bristol Myers Squibb, Eisai, Lilly, Novartis, Abbott, Bayer, Boehringer Ingleheim, Biogen, Genzyme, Glaxo Smith Kline, Johnson & Johnson, Hoffman LaRoche, Lexicon, Merck, Millenium, Neurogen, Shering Plough, Pfizer, Hoffman La Roche, Wyeth, Daiichi, Takeda (Japan’s largest pharma), Fujisawa, Ono, Mitsubishi, Shinogi, Sumitomo, Japan Tobacco
30 Cos. awaiting the new contract is sensational.
From the Shareholder's Meeting 6-16-04 - a must read
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=33246
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32890
Some Quotes:
Amber L. Morris, Emron Awwal and Karl Bruce Frank, Hoffmann-La Roche, Inc.
Fa2N-4 cells performed much like fresh human hepatocytes. These immortalized cells have potential for use as an alternative to primary human liver tissue for In Vitro Induction Studies.
Ronald Faris, Ph.D., CSO, MultiCell Technologies, Inc. We believe that MultiCell's liver cell lines will rapidly become the gold standard throughout the pharmaceutical industry for testing of new drugs," Faris said. "Our customers have been very pleased with the initial deliveries and we expect to see a ramp up of revenues as our cell lines become more integrated into their drug discovery processes."
Edward T. Maggio, Ph.D, CEO, Cengent Therapeutics Inc.
This technology promises to increase the efficiency of drug discovery and save many millions of dollars by reducing the ultimate failure rate in clinical trials, benefiting both drug companies and consumers alike."
Dr. Andrew Parkinson, CEO, XenoTech LLC
"MCT's cell lines represent a breakthrough technology that has the potential to revolutionize how the pharmaceutical industry screens new drug entities, we anticipate significant worldwide interest in MCT's cell lines."
J.B. Mills, and S. .M. de Morais, Pfizer Global Research &
Development
We investigated the use of a novel human hepatocyte clone [Fa2N-4] as an alternative reagent, which is readily available and provides a consistent, reproducible system.
These data show that use of Fa2N-4 cells in conjunction with the Invader® technology is a potential high-throughput in-vitro method for assessment of induction of ADMET targets.
Ann Randolph, Managing Director of BIOCOM (1993-1999)
"Exten is one of the most exciting companies I have seen.
MultiCell's immortalized liver cell technology platform offers enormous potential in a variety of critical markets. This company should grow rapidly and I am happy to be a part of this fine organization."
Jerry Newmin, CEO, Multicell
"We are confident that sales in even a small percent of the drug discovery and toxicology testing arena will contribute significant revenues." Again Newmin: "The minute one of these contracts comes in, we know the price of our stock will be at $2, or $5, overnight...we simply can't say with any degree of certainty when that will be. Our cells represent a big change for big pharma, and it won't happen without a great deal of thought on their part, so we have to wait it out and be patient."
"Consider this. MultiCell’s FaN2-4 human liver cell line is the only cell line in the world possessing properties which make it a suitable replacement for fresh human liver cells which are in very short supply for purposes of testing new drug candidates prior to expensive human clinical trials. MultiCell’s cell line also possesses standardized benchmarks for researchers, unlike fresh cells which vary from donor to donor. So it makes sense that big pharmas would want researchers in other companies to use these same cells as well when reviewing possible drug candidate data. It will make it much easier and far less costly for Pfizer and other large drug manufacturers to identify potential drug licensing and potential acquisition candidates from the plethora of smaller public and private biotech companies performing independent or collaborative drug research if data can be related to a well established cell testing standard. As we await sales, take comfort in knowing our FaN2-4 cells are becoming the most thoroughly tested and universally known and understood in the biotech world for good reason.
It's an amazing product. The industry has been fantasizing about getting its hands on something like this for years. Andrew Parkinson is traveling the globe spreading the news. Every major pharma is showing interest...
Also, it's therapeutic uses (liver dialysis, transplantation, etc.) and other research potential is open ended.
Exten Industries, through their two subsidiaries, MultiCell Technologies of Warwick RI and Xenogenics Corporation of San Diego, CA, is in the business of developing and marketing four major biomedical cellular products and medical devices: Hepatocyte test kits (projected $3.75 billion market worldwide), therapeutic proteins (projected $43 billion market worldwide), liver cell transplantation (projected $70+ billion market worldwide), and the SybiolR synthetic bio-liver device (a projected $2 billion market worldwide, constantly growing as the rampage of liver diseases increases.) All of these products are in the development stage.
Some Additional Important Markets
Not only toxicity test for drugs but insecticides, cosmetics, maybe household spray products, vitamins, herbs. The Federal Government could use it too, for testing illegal drugs.
MultiCell's cell lines produce therapeutic proteins that can be used in new medicines.
Hematopoietic Stem Cell Transplantation
http://content.nejm.org/cgi/content/short/344/6/463-a
•MultiCell's hepatocytes produce fully human, therapeutic proteins including albumin, and factors VIII and IX. And chief scientist Dr. Ronald Faris has generated a unique protein from the cells for which a patent application will soon be made. This protein may treat a currently untreatable acute disease with an estimated billion dollar annual market. Details will not be released until the patent application has been submitted.
Mammalian hepatocytes, a source of therapeutic proteins
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=7374
•MultiCell's hepatocytes also generate adult liver stem cells, and both the hepatocytes themselves and the stem cells could be used in allogeneic transplants to treat various types of liver disease.
•Adult liver stem cells also make ideal vectors for gene therapy directed at the human liver.
•Eventually this company will be a part of liver dialysis proceedures.
Finally, immortalized hepatocytes represent the only commercially practical method of supplying cells for a bioartificial liver, and several of these are moving toward clinical trials.
Our focus is on the generation of short-term revenue to stabilize our cash position. The additional royalties Newman says MUCL WILL NOW BEGIN TO RECEIVE from these sales by Xeno Tech may be large enough to cover our cash requirements for ongoing operations.
Thus, MUCL is now in the $3.7 billion ADME/tox hepatocyte test kit market and have what should quickly be the gold standard in that preliminary stage toxicity drug testing market.
The ADME/tox market is intended to be a side revenue stream while the company worked on toward its goals - liver cells for therapeutic applications.
MUCL is close to entering the $43 billion therapeutic protein production market.
There is the understanding that what sets MultiCell apart from any known competition is not only the non-tumeric nature of EXTI's cell lines but most importantly that they are "highly metabolic".
This is what apparently clinched the 15-year deal with Pfizer for two out of 100 or so MCT cell lines that MUCL is marketing worldwide.
MultiCell has an agreement with Pfizer for non-exclusive use of these cells. Pfizer has independently validated that these cells do in fact duplicate the response of harvested human liver cells, that they reproduce reliably, and that they are consistent in their response. Pfizer scientists are actively at work exploring new potential applications for these cells, focusing on drug development applications. The pharmaceutical giant Roche has also validated the performance of these cells.
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=29604
The claims I make are based upon published work in scientific journals by XenoTech, Pfizer, and Roche scientists. Moreover, XenoTech and Pfizer are actively presenting their results at scientific conferences, and in journals throughout the world.
Pfizer has called them (MUCL cells) "NOVEL".
Pfizer - MultiCell engagement
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=27222
Multicell immortalized hepatic cell lines are firmly in the labs of Pfizer in a 15 year exploratory deal
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=26855
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=31138
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=31599
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34671
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=35127
These cell lines have been validated for this specific purpose by Pfizer - http://home.comcast.net/~dcmack2/ISSXPoster.pdf - who signed a 15 year non-exclusive license for EXTI's cell lines after the validation. This validation was confirmed and extended by Hoffman-LaRoche - http://home.comcast.net/~dcmack2/Roche.html
- as well as by XenoTech http://homepage.mac.com/alandail/XenoTech2003.pdf
Pfizer and XenoTech are also copresenting EXTI's technology on 2-11-04 here:
http://www.cbinet.com/events/HB405/day_one.html
and again here on 6-15-04:
http://www.isciencex.com/DDI-2004%20program%20FINAL.htm
Response from Pfizer ---
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=24202
Thank you for your interest in our publication. It is our opinion that the Fa2N-4 cells are the best clonal cell line available for CYP induction studies....etc.
---------------------
It was expensive research that was done for multicell for free by Pfizer. And if you read the meeting minutes completely, you'd see that Pfizer does not have a free ride, they only have access to two of the [MUCL's 100+] cell lines.
The research Pfizer did probably would've cost millions if it had been straight up paid for in some sort of outsourcing deal. Therefore, both EXTI and PFE benefited from this collaboration. Pfizer data is included in all Xenotech's promotional material! [Who do think got all those pharmaceutical companies interested in the 1st place?]
Society for Biomolecular Screening (SBS) Identifying an Immortal Hepatocyte Cell Line Responsive to CYP Enzyme Inducers Sonia de Morais (Pfizer) Presenting on Fa2N-4
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=31082
Selling the hepatocytes does not require FDA approval.
That FDA paper is a great read. Fa2N-4 cells are the right thing at the right time,
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=24848
MUCL takes on a new shine with an FDA priority on the liver toxicity -
Interesting however that Steen notes the they "do not currently recommend the use of these immortalized hepatocytes in any studies submitted to regulatory agencies." They serve now only as drug candidate screeners.
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=26188
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=35123
It will take a while, but I look forward to the day when enough work has been done so that both XenoTech and the pharmaceutical industry can remove this caveat.
Not enough data have been gathered yet on these cells to enable a pharmaceutical company to include results obtained with them in, say, an investigational new drug (IND) application to the FDA.
But you have to remember that at one time this was the case with primary hepatocytes too. Induction studies done with primary human hepatocytes were for developmental use only - to look for hepatoxicity and possible drug/drug interactions.
Then someone pushed the FDA to consider enzyme induction data obtained with primary hepatocytes as part of IND applications. And the FDA eventually agreed to do so. That someone was Andrew Parkinson. So the regulatory approval of MUCL's cells as INDs are not far off.
Just a reminder - the main use of our cells right now in the pharmaceutical industry is early tox screening and drug/drug interaction studies for the purpose of ruling out inadequate candidates from the drug development process.
The FDA issue doesn't really come into MUCL's business model right now.
Eventually, in vitro testing with immortalized human hepatocytes will have a role in later stage drug development . But again, right now, that's not really an issue.
XenoTech's David Steen:
"Other studies are planned or ongoing to examine induction of these cells relative to other responses. Overall, we are satisfied with their performance to the extent that we now use them in contract induction screening.
Multicell's liver cells are not stem cells.These are NOT STEM CELLS but cloned adult human liver cells from an original parent human liver cell.
Multicell technology validated that it's Adult Stem Cell is more superior than hESC (human embryonic stem cell.)
Here are some disadvantages of the undifferentiated stem cell approach. Human embryonic stem cells (hESC's) are problematic when it comes to trying to differentiate them into functional mature cells:
The resultant hepatocytes are not immortalized or reproducible. Only the stem cells are. This is an important distinction. This means that whenever you want actual adult hepatocytes you have to go through the process of maturing the stem cells again. Very labor intensive.
Remember, you don't get just hepatocytes when you do this process. You get lots of other types of cells in your culture too. So you have to isolate the hepatocytes from that mixture of cells. More labor (and expense).
Next, there is no evidence that these cells can be frozen, thawed, and retain their functionality for any length of time.
Multicell's can.
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=30626
adult stem cells out ahead of embryonic stem cells
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32413
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32414
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32415
MultiCell signs a deal worth $18 million
http://www.projo.com/business/content/projo_20030821_mult21x.1f17c.html
The company now has a viable revenue stream of a minimum of $18 million over 7 years to maintain exclusivity The $18,000,000 amount is called guaranteed minimum running ROYALTIES in section 3.5. The $18 million is not over and above Sales - I also recall that Newman initially stated that these minimums were set low and would be easily exceeded. - Also in the contract (section 3.2.4), MUCL gets 10% of sales of MFE media. - 17.5 per cent of cell sales, - plus 34 per cent of license agreements if Xenotech sales exceed the limits that the royalty contract is based on. No extra revenues unless sales exceed minimums.
Royalty payments are not contingent on sales (% of sales & licenses) and are due within 6 weeks of the beginning of each quarter within the applicable Royalty period. There are no "lump sum" Royalty payments made. They are made quarterly.
Thus, overhead at EXTI is minimal
The contract with Xenotech gave MUCL an instant production and sales staff (Xenotech's) instead of having to build one out themselves. MUCL's cash burn rate is extraordinarily low, with XenoTech doing all the marketing and production right now. That leaves Dr. Faris's staff free to work on improving the cells, growing new lines, and working on our new protein.
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34794
From the Shareholder's Meeting 6-16-04
30 Cos. awaiting the new contract is sensational.
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=33246&submit=Go
average weekly throughput of 80,000 wells or more is classified as High-Throughput Screening so Faris's $500M number in the right ballpark
"450-500 HTS labs worldwide".
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34796
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34798
screening, toxicology, and ADME
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34806
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34919
450 - 500 HTS labs worldwide growing by 10-40% annually
$60,000 'sites', thats enough to sign on 20% of them
weekly throughput of 80,000 wells or more is classified as HTS in the average HTS - medicinal chemistry libraries contain hundreds of thousands of compounds. Also, they contain 1 to 2 million combinatorial chemistry structures, and tens of thousands of natural product extracts. A conversation with one pharmaceutical company's director of HTS stated that they had performed 25 screens in 2002, with a total number of wells processed at 9.9 million." - Xenotech is seeing the market more in terms of plates sold- but even just sites-
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34932
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=35061
MUCL(EXTI) has done quite-a-bit in less than a year. Exten/MultiCell has recontracted with Pfizer, contracted with XenoTech and arranged for our liver cell lines to be manufactured and sold. Delivered and sold cells to other companies before the XenoTech deal. Hired a firm to oversee the company's technology security. Gone through numerous management changes. Gone through extensive contract development and administration. Beefed up its SAB and patent protection. Had to deal with German stock market issues. Tried to find ongoing funding, and at the same time, kept operations rolling and R & D moving forward.
MultiCell developed the liver cells. This was done by MultiCell's founder, Hugo Jauregui, MD, PhD and Rhode Island Hospital. Exten was a failed real estate company that lucked into this who knows how? They stumbled along for a couple years and then they were rescued by XenoTech. Exten Industries (a holding company) no longer exists, MultiCell, a production company has merged to replace it.
This is actually an old Circe biomedical paper. Although Circe is no longer around, they funded for years Hugo Jauregui's research (MCT founder) and Barry Soloman and Zorina Pitkin are currently working at Nephros THerapuetics in Lincoln RI and maintain contact with Ronald Faris (CSO of MCT) on a fairly regular basis.
http://home.comcast.net/~dcmack2/mct_history.html
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=35500
summary
http://www.hum-molgen.de/companies/profile.php3/392
MultiCell Technologies, Inc. (MCT)
MCT expertise is the product of 25 years study of liver cell biology
http://www.multicelltechnologies.com/pdfs/MultiCell%20Fact%20Sheet.pdf?PHPSESSID=7c25ff50a73945ee52b...
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=19825
Incorporated in Delaware on April 28, 1970 under the name of "Exten Ventures, Inc
"CELL TRANSPLANTATION.
Drug-Drug interactions
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=27441
$800 mill - $1.6B to bring a drug from idea to market
PK properties can make or break a new drug, forcing companies to conduct ADME studies sooner in the discovery process
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=28018
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=29577
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=20141&submit=Go
12:00pm Development of an Automated System for Enzyme Inhibition Studies - Paul Toren, XenoTech, LLC, Lenexa, KS USA
http://labautomation.org/abstract_popup.phtml?abstractId=792
http://labautomation.org/abstract_popup.phtml?abstractId=794
Xenotech worth reading
Xenotech is actually one of the largest, privately held CRO's (contract research organizations) in the US with a reputation for excellence in drug metabolism and safety testing.
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=28039
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=5678+&submit=Go
Multicell's lines are XenoTech's top product right now, and Roche is using our cells. "Pfizer has licensed 2 cell lines".....
http://www.siliconinvestor.com/stocktalk/msg.gsp?msgid=20078646
David Steen of XenoTech has already confirmed that MUCL cells are their number one product now.
Andrew Parkinson calculated the bare minimum business he thought he could do this year, as he put the story of MUCL cells out there, and introduced a new product to his customers. He based the guaranteed royalty to MUCL on his meeting that estimate... about 2.25 million a year.
"Our studies indicate that no other form of human hepatocyte, including primary human hepatocytes, offers the =>functionality<= and consistency of MultiCell's cell lines." - Parkinson CEO of Xenotech
PR pretty much says "We have the new gold standard for the industry for all aspects of pre-clinical drug testing and we can prove it"
Andrew Parkinson, PhD. published dozens of papers on P450 function
http://ragingbull.lycos.com/mboard/boards.cgi?board=mucl&read=18612
XenoTech saw Pfizer's presentation and XenoTech then sought out EXTI and did their own independent testing before signing to be their marketing partner on these cell lines for hepatocyte test kits. http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20031010005...
http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20031030005...
Multicell worth reading
An overview
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=20395
http://ragingbull.lycos.com/mboard/boards.cgi?board=CLB00413&read=9546
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=28040
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=17331
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=29434
XenoTech mentioned Multicell as breakthrough technology
explanation of Multicell therapeutic proteins
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=5696
http://www.siliconinvestor.com/stocktalk/msg.gsp?msgid=19320215
http://clearstation.etrade.com/cgi-bin/bbs?post_id=4948777%20%20overview
Novel Strategies for Immortalization of Human Hepatocytes
http://www.blackwell-synergy.com/links/doi/10.1046/j.1525-1594.2001.025007529.x/full/
A review for some, a primer for newbies:
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34571
Here's the unofficial MUCL(EXTI) investor site: http://exti.info/
Exten[ now Multicell] is the only company with immortilized human liver cells used for drug development.
the key words "without any significant loss in data quality" says it all. Why have any loss of quality when you can have no loss and/or an unlimited supply?
http://home.comcast.net/~dcmack2/extimain.html#whois
Here's the official MUCL(EXTI) web site: http://exten.com/
Liver Dialysis http://exten.com/exten2/sybiol.htm
here's another site with a great collection of MUCL(EXTI) info:
http://www.hannibalsweb.com/cgi-bin/hannibalsweb/ikonboard.cgi?s=61740b76cd8a5f990fe222ce30fd4d10;ac...
Xenogenics Scientific Advisory Board - Liver Dialysis
http://www.exten.com/exten2/teamxenogenics.htm
MUCL(EXTI) review http://turnaroundpicks.com/exti.htm
Multicell Technologies
http://www.multicelltechnologies.com/
MUCL(EXTI) message boards
http://www.siliconinvestor.com/stocktalk/subject.gsp?subjectid=17807
http://ragingbull.lycos.com/mboard/boards.cgi?board=BB%3AMUCL&origsymbols=MUCL
http://finance.groups.yahoo.com/group/EXTIhead/
http://quotes.freerealtime.com/dl/frt/C?IM=quotes&symbol=MUCL&type=MessageBoard
http://www.hum-molgen.de/companies/profile.php3/392
MUCL yahoo information
http://finance.yahoo.com/q?s=MUCL.OB
http://www.turnaroundpicks.com/exti.htm
http://centerspan.org/pubs/liver/brems1.htm
http://research.businessweek.com/business_summary.asp?Symbol=MUCL
EXTI synopsis
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=30032
EXTI INFO
http://home.comcast.net/~dcmack2/exti.html
http://quotes.freerealtime.com/dl/frt/C?IM=quotes&symbol=MUCL&type=MessageBoard
http://finance.groups.yahoo.com/group/EXTIhead/
http://home.comcast.net/~dcmack2/MCTpics.html
http://home.comcast.net/~dcmack2/extilinks.html
http://home.comcast.net/~dcmack2/pregate.html
Informative posts - replace EXTI with MUCL in the URLs
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=21009
MUCL/EXTI news links
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34103
Here are some of the main people involved in MUCL's future
either as officers of Multicell or on a MUCL Scientific Advisory Board with more than a hundred patents registered in their names.
"The immortalized hepatocytes promise to contribute dramatically to improvements in candidate qualification and preclinical development. Drug companies may soon benefit from longitudinal comparison data across many candidates and years, all using the same near-normal, predictable, immortalized human hepatocytes."
More at http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=26638
David Steen, XenoTech
Dr. Maggio (MUCL board member) commented, "Exten Industries' cell-based toxicological and drug screening technologies address certain critical needs among pharmaceutical and biotech companies to make more accurate assessments of the likely success of new drug candidates before they are actually placed into clinical trials. This technology promises to increase the efficiency of drug discovery and save many millions of dollars by reducing the ultimate failure rate in clinical trials, benefiting both drug companies and consumers alike."
Here's his company: http://www.cengent.com/corporate_info.html
About Jerry Newman CEO
http://www.sandiegometro.com/1997/jul/fixit.html
http://www.ceocfointerviews.com/interviews/ExtenInd.htm
Newman simply reinforced the clear perception that they're in a good place, and each day gets us closer to what they have worked toward all along: big contracts with big pharma.
At MCT we respect the importance of intellectual property protection. All customer information is maintained in strict confidence under appropriate non-disclosure agreements.]
Dr. Stephen Mon Wei Chang (SAB)
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=33850
Dr. Chang on SAB 40 patents
http://biz.yahoo.com/bw/040623/235671_1.html
Also guess who's name shows up on most of Chiron's Hepatitis Tehcnology Patents? that would be Stephen M W Chang
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34210
therapeutic protein liver cells make immunoglobulins
http://www.himss.org/asp/ContentRedirector.asp?ContentId=51399
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=35344
Sangeeta Bhatia (SAB)
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=30478
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=30455
Sangeeta Bhatia drug toxicity studies
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32418
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32420
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32421
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32423
Dr. Bhatia continues to work on her bioreactor research - again costs us nothing. And there's a dark horse there. Bhatia is still involved with bio-sensors and the Defense Dept.
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32643
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=35335
MultiCell's future - Dr. Faris's stem cell patent
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32430
"MCT is focusing on a unique protein not currently made by other cells. It addresses an ‘acute disease’ for which there is no treatment. The estimated market size for treating this acute disease is $1 billion. He can not say more at this time as they intend to apply for a patent. He referred to it as the “magic x protein.”" Faris's patent
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34620
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34621
Dr. Faris’s Protein X NIH grant application of 2002
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34688
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34708
Doug Hixson Phd (SAB)
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=30447
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=31246
MultiCell's cellular product expertise also enables production of liver-derived therapeutic proteins. Such proteins could ultimately be used to treat a number of liver related diseases such as hemophilia, primary immune deficiencies and emphysema.
MultiCell has a unique TP production technology. Immortalized hepatocyte biofactories (TM). examples of companies with a similar asset already reaping revenues or partnerships
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=35419
I just became a share-holder. Having the most advanced technology for what could be an extremely wide spread treatment plus the micro-cap is hard to resist.
As a board member of MUCL subsidiary, Xenogenics, I will limit myself strictly to public information published by ourselves or our new partners.
T. Scott Brassfield MD
Dr. Scott Brassfield's comments "and, what we may be most excited about, therapeutic proteins." Therapeutic Proteins
This is huge. As good of a thing as they have going presently - with their un-rivalled product just now taking root in the 3 to 4 billion $ hepatocyte test kit mkt., these proteins are the real biggie. No worry of cross species viral transmission, no (or much less) rejection by our own antibodies to the proteins since they're fully human. oh, and no real competition as far as cost & quality goes. I don't see how they won't get a nice chunk of the market here. (which is estimated at around 40 billion).
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=5678
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=7682
http://ragingbull.lycos.com/mboard/boards.cgi?board=mucl&read=18519
Officers
http://ragingbull.lycos.com/mboard/boards.cgi?board=mucl&read=17331
See what the MUCL officers is saying about it's cell lines:
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=17331
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32044
The following names appear in EXTEN INDUSTRIES INC's SEC filings.
http://www.edgar-online.com/brand/yahoo/people/companypeople.asp?cik=811779
Management of the Company's intellectual property is our top priority. - Dr. Ronald Faris, Chief Science Officer of MultiCell
"The key is to manage the intellectual property of the company for maximum shareholder value."
“We believe that MultiCell’s liver cell lines will rapidly become the gold standard throughout the pharmaceutical industry for testing of new drugs,” Faris said. “Our customers have been very pleased with the initial deliveries and we expect to see a ramp up of revenues as our cell lines become more integrated into their drug discovery processes.”
Dr.Faris "He currently has NIH funding to develop therapeutic applications for adult liver stem cells."
Here are patents of the MultiCell Inc Scientific Advisory Board (SAB):
Edward T. Maggio, Ph.D Patents
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32385
Douglas Hixson, PhD list of Patents
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32386
Sangeeta Bhatia PhD, MD List of Patents
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32387
Stephen Chang PhD Patents
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32388
MultiCell Inc., Patents
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=32389
Liver Assist Device Patent
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=11606
http://exten.com/exten2/sybiol.htm
http://www.lumc.edu/feature/top.htm
MUCL is fully reporting by all SEC standards
http://www.sec.gov/Archives/edgar/data/811779/000108638003000061/extq0803.htm
There are approximately 121 million shares outstanding.
The people [insiders] listed on the S3 currently own around 45% of the outstanding shares....retail and restricted. Raging Bull MUCL Club hold approximately 26% percent of the float. Insiders bought more than they sold.
"As of Feb 29, 2004 warrants to purchase 22,234,584 shares of common stock were outstanding and exercisable."
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=31600
These warrants have been issued and have accumulated over time for loans, services, etc. going back several years.
In other words, my concern was misplaced. The 22,000,000 plus warrants were in existence and accounted for in the annual report.
The warrants will expire from January 2008 to January 2013.
The only part of the 10Q I was uncomfortable with is the continued mention of the defaulted loans (first mentioned last November). I know this was expected, since revenues could not have covered the defaulted amounts.
"Jerry Newmin has a record of resisting reverse stock splits as long as he has been with the Company. Barbara Corbett, IR/PR
MUCLinvestor@aol.com Barb Corbett MUCL secretary Shareholder information
I was surprised by the amount of prior experience Corbett has prior to coming on board in 1997. She had prior experience in investor marketing for brokerage firms, an advertising/marketing manager and ten years owning and managing an advertising agency.
Human Liver Cell Culture Facility at SRI International - donated livers
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34518
=============================
MUCL is in a quiet period so it was a good time to buy.
This is a long term hold. Remember that MUCL has low overhead expenses since it's production and marketing expenses are carried by Xenotech who pays MUCL somewhere around $2.2 million a year (up to $18 million) for the rights to market these Fa2N-4 cells. Never-the-less, MUCL is low on cash and a small amount of further dilution in shares outstanding is possible till Big pharma contracts (above) kick in.
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34624
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34654
http://ragingbull.lycos.com/mboard/boards.cgi?board=MUCL&read=34733
This offers an oppurtunity to accumulate more shares in this price range for an eventual blast off to higher levels.
Senior people in big pharma say that the worst case is that MUCL gets bought by a GSK, Aventis, or Pfizer... to have technology like this is etremely valuable and the investment is minimal and worthwhile (especially when a company like Pfizer dumps $8 billion+ in R&D annually).
On a September 30, 2003 email reply form Greg Szabo re: the possibility of Xenotech being an acquisition candidate. Here is his reply...
As you well know, it has been a long hard road. XenoTech really is a great partner with terrific connections. As we come out with new products, they should be very helpful as well. As far as acquisition, you never know. They are privately held so it may make sense some day. greg
One investor's discussion with David Steen:
-Acquisition? no, not a very good possibility. -Xenotech is very comfortable as a private entity. This will not change. David Steen told a shareholder: "This company is not going public"!
Anyone have any strategies on SHO yet?
Keep an eye on MUCL. Contract news out yesterday and alert from SmallCapCenter.com this AM. This little Company has huge potential. Followed it for several years.
One can only hope!
hardest part is being a Gator Fan (post Spurrier!)